<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Desert Foot 2023: Caring for Patients with DFUs

By Susan Paquette on 3/12/24 9:30 AM

Established and innovative new biologic products share space at Desert Foot 2023.

The diabetic population in the US continues to rise, with the Centers for Disease Control and Prevention (CDC) estimating that ~11.3% of US adults will be diagnosed with diabetes in 2021, the vast majority having Type II. The number of diabetics is even higher in the Veterans Health Administration (VHA), where one in four (25%) has diabetes, according to recent statistics published in VA News.

According to the Mayo Clinic, Type II diabetes can eventually lead to high blood sugar levels, which can cause disorders of the circulatory, nervous and immune systems. One ailment that often arises with diabetes is the occurrence of a diabetic foot ulcer (DFU) due to poor blood flow and neuropathy that many of these patients experience. The prevalence of a DFU varies with age, ranging from two percent in younger adults to eight percent in adults 65 and older.

In this article, which can be downloaded here, SmartTRAK reports on:

  • Skin Substitute Market Leaders at Desert Foot
    • Four of the top five US skin substitute/ CTP companies had a strong presence at the meeting. They were ... (read more)

  • Companies and innovations that caught SmartTRAK’s attention, including:
    • MicroVascular Tissues (MVT) - Featured mVASC, an off-the-shelf human tissue allograft consisting of ... (read more)
    • Fidia US - Showcased its newly launched Wound Care line of products, including ... (read more)
    • Merakris Therapeutics - Provides Dermacyte Amniotic Wound Care Matrix (Dermacyte Matrix) to the market as a skin substitute. However, at Desert Foot, the company discussed its ongoing clinical trial to investigate ... (read more)
    • Omeza - Presented its unique Omeza Complete Matrix (OCM) product and started the presentation by stating, “Omeza is not a Collagen Dressing or Product!! OCM is not a Dressing.” The company described OCM as ... (read more)

      To download and read the complete "Desert Foot 2024" article by Susan Paquette, SmartTRAK VP & General Manager, Wound, just click the button below.
      Read the Article
Topics: Wound Care
Continue Reading
3 min read

What Impact will GLP-1 Agonists have on Chronic Wounds?

By Kris Flinn on 3/5/24 2:24 PM

With many believing that GLP-1 agonists should be considered a “wonder drug,” SmartTRAK explores what impact their use could have on the market for wound care.

S martTRAK  estimates  that there were 77.7MM chronic wounds worldwide (US, Europe, Japan, Australia, Canada, Brazil, China and India) in 2022, of which 41.4MM were hard-to-heal. Wound numbers are forecast to grow at a five-year CAGR of +0.8%, which is higher than the forecasted population growth of +0.3% but below the growth of those aged over 65 years old.
 
In this article, SmartTRAK provides an overview of GLP-1 agonists, explores the possible impact these drugs will have on the conditions that drive wound prevalence and advises on how the outcomes will influence future estimates.
 
Among the topics covered in this article are:
  • What are GLP-1 Agonists?
    GLP-1 agonists are a class of drugs mimicking the action of a hormone called glucagon-like peptide 1. The drugs stimulate glucose-dependent insulin release from the pancreas. A range of agonists have been developed and launched, with the first product being ... (read more)

  • What is the Future for GLP-1 Agonists?
    Financial indicators suggest that GLP-1 agonists are expected to expand significantly in use around the world. The two companies with drugs licensed for weight loss have seen record share price growth are ... (read more)

  • What Impact Are GLP-1 Agonists Expected to Have on Diabetes and Obesity?
    When GLP-1 agonists were launched in 2005, they required twice daily injections. This was driven by the rapid elimination, or short half-life, of the compounds. With further development, companies have improved usability and weekly injections and ... (read more)
Topics: Wound Care
Continue Reading
3 min read

Advanced Wound Dressings: 2024 Market Outlook

By Lennart Stadler on 2/20/24 9:30 AM

From OEM manufacturers getting dressings approved in the US to pressure injury prevention focus - SmartTRAK takes a closer look at what to keep an eye on in 2024.

SmartTRAK forecasts the WW Advanced Wound Dressing Market will grow at a 5-year CAGR of +5.2%. The market grew +5.2% in Q323 and +5.6% in the first three quarters of 2023. Advanced Wound Dressings is a market spread relatively evenly across geographies, with Europe currently representing a 44.1% share of the 2023 worldwide (WW) market, the US representing 27.9% and the ROW 28.0%.

Looking ahead, SmartTRAK sees three trends continuing in 2024. They are:

  • Growing Use of OEM Manufacturers in the US
    In the US, most dressings require 510(k) clearance by the FDA. A strong trend in recent years is that original equipment manufacturer (OEM) providers have been getting their products approved for sale in the US and then ... (read more)

  • Major Players Investing in Infrastructure
    Another trend of interest is more activity than usual from leading companies investing in infrastructure. SmartTRAK examines recent events and the potential drivers behind those decisions ... (read more)

  • Growth in Dressings for Pressure Injury Prevention
    SmartTRAK expects the use of dressings for pressure injury prevention to be a key growth driver in the Advanced Wound Dressing Market in the coming years. The trend is supported by an increasing body of evidence indicating that ... (read more)

SmartTRAK has developed an in-depth analysis of the pressure injury prevention market, including the market size for the US, Europe, and the rest of the world (ROW), five-year forward forecasts, clinical and laboratory evidence, key drivers of market growth, and product technologies and claims. To find out more, please click here.

To download and read the complete "Advanced Wound Dressings: 2024 Market Outlook" by Lennart Stadler, SmartTRAK GM, OUS & Sr. Analyst, Wound and Anikó Szekér, SmartTRAK Sr. Analyst, Wound, just click the button below. Read the Article

Continue Reading
3 min read

HMP Global’s Wound Care Learning Network Partners with SmartTRAK to Provide Wound Care Market Intelligence, Analysis

By SmartTRAK on 2/15/24 1:44 PM

Rich ongoing data updates and comprehensive expert analyses will deliver evolving market trends and conditions for wound care professionals.

MALVERN Pa., (February 15, 2024) — HMP Global’s Wound Care Learning Network (WCLN) today announced a partnership with SmartTRAK, a comprehensive life sciences market intelligence solution providing real-time market data and analysis along with expert insight on evolving trends and conditions of interest for wound care professionals.

Topics: Wound Care
Continue Reading
2 min read

Wound Debridement 2024 Outlook

By Kris Flinn on 2/12/24 12:08 AM

With the eyes of the wound care world focused on the markets for Skin Substitutes and Antimicrobials, SmartTRAK discusses how 2024 could be a disruptive year for Debridement.

SmartTRAK forecasts that the WW Debridement Market will grow at a 5-year CAGR of +4.9% to 2027E, at which point it will be valued at over half a billion dollars. In this article, Kris Flinn, SmartTRAK's Sr. Analyst, Wound, does a deep dive into what's ahead for the debridement market, including the indexed growth for Advanced Wound Care (AWC) and Debridement for each of the three SmartTRAK geographical regions: US, Europe (EU) and the Rest of World (ROW).

Among the topics covered in detail in this market outlook article, which can be downloaded here, are:

  • Chemical Debridement Growing Pains
    Chemical Debridement is the smallest of the Debridement segments The WW 5-year CAGR of +69.1% promises a brighter future, with usage growing across all geographic regions, including ...
  • New Enzymatic Debridement Technologies Continue to Build Evidence
    MediWound presented Phase IIB clinical trial results for bromelain-based EscharEx at the SAWC Spring meeting in May 2023. The 120-patient venous leg ulcer, multicenter, randomized control trial compared EscharEx with a placebo gel vehicle and a non-surgical standard of care (SoC). Results showed...
Continue Reading
4 min read

SmartTRAK's Top 12 Blog Posts of 2023

By Thomas Wallick on 1/30/24 1:04 PM

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors.  Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.

  1. Could Reverse Hips Change the Total Hip Game?
    Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement

  2. Three Ortho Robotics Companies to Watch in 2023
    SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market.

  3. Saluda Medical: Changing the Game in Spinal Cord Stimulation
    Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.

    Request a Demo of the SmartTRAK Business Intelligence Platform

Continue Reading
2 min read

Combating Biofilms at Every Stage of Wound Care: An Interview w/ Hybrisan CEO Chris Mortimer

By Kris Flinn on 1/17/24 11:33 AM

SmartTRAK talks with Hybrisan CEO Dr. Mortimer to discuss the challenge of biofilms and the Company’s journey to bring its WoundSan technology to market.

The AWC Summit, held biannually, brings together established companies, start-ups, research organizations and various industry stakeholders. SmartTRAK previously covered the US event in July 2023 in Boston, MA, focusing on advancing the commercialization of new technologies in wound care, and was in London, UK to cover the EU Summit

A regular feature of the Advanced Wound Care (AWC) Summit is the Innovation Showcase. At the event in London, six companies took turns pitching their technologies, with the delegates voting to award one company as the winner.
Following the vote, the winning organization was announced as Hybrisan. SmartTRAK talked with Hybrisan CEO Dr. Mortimer to discuss its Woundsan technology and the challenge of combating biofilms in wound care. The interview can be viewed below and a transcript can be downloaded by clicking the button:

 

Download the Transcript
Future Events

The next AWC Summit will be the US edition and will take place in Boston, MA on the 16thand 17thof April, 2024. SmartTRAKwill be in attendance and will be discussing the latest insights within wound care. More information on the event is available  here. The next European event is planned for late 2024, with details to follow.

Topics: Wound Care
Continue Reading
4 min read

AWC Summit EU 2023: European and US Growth Explored in London

By Kris Flinn on 1/15/24 3:40 PM

SmartTRAK joined industry colleagues in London to explore new technologies at an exciting time in wound care.

SmartTRAK has determined the 2022 European Advanced Wound Care (AWC) Market grew at a +4.4% rate compared to 2021. AWC in Europe is dominated by Advanced Dressings, with Wound Biologics and External Devices only accounting for 18.6% of total revenue. This is in stark comparison with the US AWC Market in which highly-priced treatments such as Wound Biologics (44.4% share in US) and External Devices (28.4%) have favorable reimbursement levels. SmartTRAK forecasts both markets to benefit from healthy growth in the next five years despite some looming reimbursement challenges. In the US, Medicare Administrative Contractor LCD changes to skin substitutes (as featured in this article) could lead to reduced usage of the products in the hospital outpatient and physician office sites of care, and in Germany reimbursement on silver products is due to end in late 2024.
 
At the event in London, contributors discussed areas as varied as adapting to home care and remote monitoring, launching products in the US and keeping up with the changing European regulatory landscape as the Medical Device Regulation (MDR) replaces the old Medical Device Directive (MDD). SmartTRAK was present and Lennart Stadler, SmartTRAK GM and OUS Sr. Analyst, Wound, presented the latest market insights from the global AWC space, including an overview of the recent corporate activity (Figure 1).

The session that generated the greatest discussion was titled  “Investment 101.”   Asif Shahinsha from PharmaVentures , Pierre Socha from  Amadeus Capital Partners  and Gabor Heltovics from   NLC Health Ventures  discussed the best approaches toward fundraising and which companies have been successful. 

A regular feature of the AWC Summit is the Innovation Showcase. At the event in London, six companies took turns pitching their technologies, with the delegates voting to award one company as the winner.  The companies were:
 

The Innovation Showcase

At the event in London, six companies took turns pitching their technologies, with the delegates voting to award one company as the winner. The companies were:

  • Amferia– a Swedish company that is developing antimicrobial peptides for use in a variety of applications and carriers. The Company has made an FDA submission and is currently operating within the veterinary market.
  • Healthy.io– an Israeli digital organization that has launched Minuteful for Wound. The app is being used widely in the UK and has shown positive impacts on treatment, such as a 33% reduction in antimicrobial usage.
  • Hybrisan– a Welsh medtech product development company that has an antibiofilm technology called WoundSan. The solution can be used alongside existing antimicrobials such as silver and the company is in discussions with potential commercial partners.
  • Plasma4– a British cold plasma company spun out from the University of Lancaster. The product applies the treatment through a dressing.
  • SmartWound– a British biophysical chemistry company that has developed infection-sensing technologies within dressings or via a swab. The Company believes the test can be undertaken for around $6, making it less expensive than other alternatives.
  • SolasCure– this UK-based business has been visible on the market for a few years with its enzymatic debridement technology, Aurase. The product is moving towards its IIb clinical study and is unlikely to reach the market before 2028.
Following the vote, the winning organization was announced as Hybrisan. SmartTRAK talked with Hybrisan CEO Dr. Chris Mortimer to discuss the challenge of biofilms and the company’s journey to bring its WoundSan technology to market.

That interview, titled "Combating Biofilms at Every Stage of Wound Care," is featured in this post on the SmartTRAK blog.

To download and read the "AWC Summit EU 2023: European and US Growth Explored in London" article by Kris Flinn, SmartTRAK Sr. Analyst, Wound, just click the button below. Read the Article
 
Topics: Wound Care
Continue Reading
2 min read

Reimagine Wound Care Possibilities at CAMPS 2024

By SmartTRAK on 1/12/24 9:30 AM



MIAMI, FLORIDA — We are thrilled to announce that SmartTRAK's Susan Paquette, VP of Wound Care, will be speaking at the inaugural Cellular, Acellular and Matrix-like Products (CAMPs) Wound Care Summit 2024, set to take place on March 13-14 in the vibrant city of Miami. This two-day clinical and scientific summit aims to empower physicians and wound care professionals to achieve optimal outcomes, strategize for regulatory approval, and navigate reimbursement processes for CAMPs.

Topics: Wound Care
Continue Reading
2 min read

SAWC Fall 2023: Skin Substitutes Reign Again

By Susan Paquette on 12/12/23 9:30 AM

Over the last 10+ years, the market for skin substitutes has been turbulent with new technologies and products being launched and reimbursement changes occurring for the various sites of care. SmartTRAK highlights a few of these based on the recent SAWC Fall meeting.

Skin substitutes, also referred to as CTPs (cellular and/or tissue-based products) or CAMPs (cellular, acellular and matrix‑like products), remained front and center at the Symposium on Advanced Wound Care (SAWC) Fall meeting held in Las Vegas on November 2-5, 2023. The strong presence of these products mirrors a similar trend in the overall US Advanced Wound Care (AWC) market. For Q323, skin substitutes alone account for 37% of the US AWC market, more than Negative Pressure Wound Therapy (NPWT) or Advanced Dressings, according to an analysis of SmartTRAK Financial Dashboard.

In this article, SmartTRAK discusses in detail:

  • The Migration of Skin Substitutes Over the Years
  • Which Synthetics are Gaining Attention
  • New Companies–Unique Technology and Innovations
  • Health Policy Dynamics–Reimbursement and Advocacy
  • The Future of US-Based AWC Companies
  • The Potential for Acquisitions on the Horizon

To download and read the complete detailed "SAWC Fall 2023: Skin Substitutes Reign Again" article by SmartTRAK's Susan Paquette, VP & General Manager, Wound and Terry Hayslett, Sr. Analyst, Wound, just click the button below. Read the Article

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles